As on Wednesday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) got off with the flyer as it spiked 4.88% to $18.93, before settling in for the price of $18.05 at the close. Taking a more long-term approach, ARWR posted a 52-week range of $17.05-$36.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -2.87% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 49.64%. This publicly-traded company’s shares outstanding now amounts to $124.38 million, simultaneously with a float of $115.84 million. The organization now has a market capitalization sitting at $2.36 billion. At the time of writing, stock’s 50-day Moving Average stood at $20.85, while the 200-day Moving Average is $23.00.
Arrowhead Pharmaceuticals Inc (ARWR) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Arrowhead Pharmaceuticals Inc’s current insider ownership accounts for 6.90%, in contrast to 76.46% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’25, this organization’s Chief Discovery/Trans Medicine sold 32,729 shares at the rate of 19.82, making the entire transaction reach 648,824 in total value, affecting insider ownership by 272,122. Preceding that transaction, on Jan 06 ’25, Company’s COO and General Counsel sold 29,184 for 19.82, making the whole transaction’s value amount to 578,539. This particular insider is now the holder of 535,201 in total.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
Arrowhead Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 49.64% and is forecasted to reach -3.39 in the upcoming year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Let’s observe the current performance indicators for Arrowhead Pharmaceuticals Inc (ARWR). It’s Quick Ratio in the last reported quarter now stands at 6.74. The Stock has managed to achieve an average true range (ATR) of 1.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 663.53.
In the same vein, ARWR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.00, a figure that is expected to reach -0.41 in the next quarter, and analysts are predicting that it will be -3.39 at the market close of one year from today.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Through scrutinizing the latest numbers posted by the [Arrowhead Pharmaceuticals Inc, ARWR], it can be observed that its last 5-days Average volume of 1.88 million was better the volume of 1.6 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 29.04% While, its Average True Range was 1.18.
Raw Stochastic average of Arrowhead Pharmaceuticals Inc (ARWR) in the period of the previous 100 days is set at 18.27%, which indicates a major fall in contrast to 38.94% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.08% that was lower than 65.44% volatility it exhibited in the past 100-days period.